The management of thrombosis in pregnancy: Role of low-molecular-weight heparin
暂无分享,去创建一个
[1] F. Spertini,et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. , 2006, Blood.
[2] J. Gris,et al. More on: factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case‐control ‘NOHA First’ study , 2006, Journal of thrombosis and haemostasis : JTH.
[3] A. Wijesiriwardana,et al. Fondaparinux as anticoagulant in a pregnant woman with heparin allergy. , 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[4] I. Greer,et al. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. , 2005, Blood.
[5] B. Brenner,et al. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE‐ENOX study , 2005, Journal of thrombosis and haemostasis : JTH.
[6] J. Merlo,et al. Low molecular weight heparin for repeated pregnancy loss: is it based on solid evidence? , 2005, Journal of thrombosis and haemostasis : JTH.
[7] H. Magnani,et al. Treatment of 51 pregnancies with danaparoid because of heparin intolerance , 2004, Thrombosis and Haemostasis.
[8] R. Zotz,et al. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications , 2004, Journal of thrombosis and haemostasis : JTH.
[9] J. Gris,et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. , 2004, Blood.
[10] C. Dempfle. Minor transplacental passage of fondaparinux in vivo. , 2004, The New England journal of medicine.
[11] A. Kaider,et al. Prospective evaluation of coagulation activation in pregnant women receiving low-molecular weight heparin , 2004, Thrombosis and Haemostasis.
[12] L. Barbour,et al. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. , 2003, American journal of obstetrics and gynecology.
[13] M. Khamashta,et al. Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[14] C. Rodeck,et al. Post-partum haemorrhage: definitions, medical and surgical management. A time for change. , 2003, British medical bulletin.
[15] D. Back,et al. A Longitudinal Study of Maternal Dose Response to Low Molecular Weight Heparin in Pregnancy , 2003, Obstetrics and gynecology.
[16] S. Kahn,et al. Thrombophilic disorders and fetal loss: a meta-analysis , 2003, The Lancet.
[17] D. Hoppensteadt,et al. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. , 2003, Hematology/oncology clinics of North America.
[18] J. Kelton,et al. Congenital Thrombophilic States Associated with Venous Thrombosis: A Qualitative Overview and Proposed Classification System , 2003, Annals of Internal Medicine.
[19] F. Stewart,et al. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series , 2002, BJOG : an international journal of obstetrics and gynaecology.
[20] A. Eldor. The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy. , 2002, European journal of obstetrics, gynecology, and reproductive biology.
[21] J. Wallace,et al. Tissue Factor Expression on Monocyte Subpopulations during Normal Pregnancy , 2002, Thrombosis and Haemostasis.
[22] R. Kaaja,et al. Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy. , 2002, Thrombosis research.
[23] V. Hiilesmaa,et al. Postpartum Bone Mineral Density in Women Treated for Thromboprophylaxis with Unfractionated Heparin or LMW Heparin , 2002, Thrombosis and Haemostasis.
[24] Z. Miedzybrodzka,et al. Prothrombotic Genotypes Are not Associated with Pre-eclampsia and Gestational Hypertension: Results from a Large Population-based Study and Systematic Review , 2002, Thrombosis and Haemostasis.
[25] C. Jégo,et al. Low Molecular Weight Heparins , 2012, Drugs.
[26] A. Borel‐Derlon,et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies , 2001, BJOG : an international journal of obstetrics and gynaecology.
[27] D. Henderson-smart,et al. Antiplatelet agents for preventing and treating pre-eclampsia. , 2007, The Cochrane database of systematic reviews.
[28] oseph,et al. INCREASED FREQUENCY OF GENETIC THROMBOPHILIA IN WOMEN WITH COMPLICATIONS OF PREGNANCY INCREASED FREQUENCY OF GENETIC THROMBOPHILIA IN WOMEN WITH COMPLICATIONS OF PREGNANCY , 2000 .
[29] D. Hoppensteadt,et al. An update on heparins at the beginning of the new millennium. , 2000, Seminars in thrombosis and hemostasis.
[30] V. Pettilä,et al. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. , 1999, Thrombosis research.
[31] R. Venkataramanan,et al. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. , 1999, American journal of obstetrics and gynecology.
[32] B. Brenner,et al. Safety of Low-Molecular-Weight Heparin in Pregnancy: A Systematic Review , 1999, Thrombosis and Haemostasis.
[33] I. Greer. Thrombosis in pregnancy: maternal and fetal issues , 1999, The Lancet.
[34] J. Ray,et al. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. , 1999, Obstetrical & gynecological survey.
[35] J. Bonnar,et al. Can more be done in obstetric and gynecologic practice to reduce morbidity and mortality associated with venous thromboembolism? , 1999, American journal of obstetrics and gynecology.
[36] L. Duley. Aspirin for preventing and treating pre-eclampsia , 1999, BMJ.
[37] H. Cohen,et al. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin , 1999, British journal of obstetrics and gynaecology.
[38] A. Many,et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. , 1999, The New England journal of medicine.
[39] M. Blombäck,et al. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[40] I. Greer,et al. Activated Protein C Sensitivity, Protein C, Protein S and Coagulation in Normal Pregnancy , 1998, Thrombosis and Haemostasis.
[41] H. Ostermann. Low molecular weight heparins , 1998, Der Internist.
[42] K. Maršál,et al. Factor V Q506 Mutation (Activated Protein C Resistance) Associated with Reduced Intrapartum Blood Loss – a Possible Evolutionary Selection Mechanism , 1998, Thrombosis and Haemostasis.
[43] M. Blombäck,et al. Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[44] B. Brenner,et al. Thrombophilia and Fetal Loss , 2003, Blood reviews.
[45] H. Geijn,et al. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies , 1997, British journal of obstetrics and gynaecology.
[46] I. Greer,et al. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy , 1997, British journal of obstetrics and gynaecology.
[47] H. Cohen,et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) , 1997, BMJ.
[48] W. Kutteh. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. , 1996, American journal of obstetrics and gynecology.
[49] R. Farquharson,et al. Bone density studies in pregnant women receiving heparin. , 1996, European journal of obstetrics, gynecology, and reproductive biology.
[50] J. T. ten Cate,et al. The Risk of Abortion and Stillbirth in Antithrombin-, Protein C-, and Protein S-deficient Women , 1996, Thrombosis and Haemostasis.
[51] J. Hirsh,et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. , 1995, The New England journal of medicine.
[52] V. Kakkar,et al. Long‐term administration of heparin and heparin fractions and osteoporosis in experimental animals , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[53] H. Sjöberg,et al. Bone mineral density during long‐term prophylaxis with heparin in pregnancy , 1994, American journal of obstetrics and gynecology.
[54] J. Steiner,et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. , 1994, American journal of obstetrics and gynecology.
[55] T. Brighton,et al. Antiphospholipid antibodies and thrombosis. , 1994, Bailliere's clinical haematology.
[56] A. Kher,et al. Low Molecular Weight Heparin as Thromboprophylaxis in Pregnancy , 1994 .
[57] K. Nicolaides,et al. Use of Low Molecular Weight Heparin in Pregnancy , 1992, Thrombosis and Haemostasis.
[58] Jeffrey S. Ginsberg,et al. Use of antithrombotic agents during pregnancy. , 1992, Chest.
[59] R. Silver,et al. Outcome of Treated Pregnancies in Women With Antiphospholipid Syndrome: An Update of the Utah Experience , 1992, Obstetrics and gynecology.
[60] J. Denburg,et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. , 1992, Blood.
[61] J. Denburg,et al. The Relationship of Antiphospholipid Antibodies to Thromboembolic Disease in Systemic Lupus Erythematosus: A Cross-Sectional Study , 1991, Thrombosis and Haemostasis.
[62] N. Lindvall,et al. Osteopenia in pregnancy during long‐term heparin treatment: A radiological study post partum , 1991, British journal of obstetrics and gynaecology.
[63] H. Lawson,et al. Maternal Mortality in the United States, 1979-1986 , 1990, Obstetrics and gynecology.
[64] M. Levine,et al. Risks to the Fetus of Anticoagulant Therapy During Pregnancy , 1989, Thrombosis and Haemostasis.
[65] P. Mombaerts,et al. Fibrinolytic Response to Venous Occlusion and Fibrin Fragment D-Dimer Levels in Normal and Complicated Pregnancy , 1987, Thrombosis and Haemostasis.
[66] D. Bergqvist,et al. Late venous function in the leg after deep venous thrombosis occurring in relation to pregnancy. , 1986, British journal of obstetrics and gynaecology.
[67] B. Åstedt,et al. Isolation of a new specific plasminogen activator in hibitor from pregnancy plasma , 1986, British journal of haematology.
[68] I. Nilsson,et al. Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women , 1986, British journal of haematology.
[69] T. Meade,et al. Haemostasis in Normal Pregnancy , 1984, Thrombosis and Haemostasis.
[70] M. Blombäck,et al. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition. , 1981, Gynecologic and obstetric investigation.
[71] B. Bjerre,et al. Maternal Mortality in Sweden , 1964, Acta obstetricia et gynecologica Scandinavica.
[72] G. Lennon,et al. Primary postpartum haemorrhage , 2002, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.